Biopharma player, Immuron Released Corporate Presentation

May 17, 2019 05:34 PM AEST | By Team Kalkine Media
 Biopharma player, Immuron Released Corporate Presentation

An Australia-based commercial and clinical-stage biopharmaceutical company, Immuron Limited (ASX: IMC) focuses on treatment of infectious diseases with oral immunoglobulin-based therapies, targeting the human gut immune system and the gut microbiome.

The company has one marketed product, which provides proof of concept for its Oral Immune Technology Platform ‘Travelan®’ which is used for the prevention of travellers’ diarrhoea. Presently, Travelan® is marketed in Australia, USA and Canada.

There are two other clinical assets of the company apart from Travelan®:

  • IMM-124E - It is in Phase 2 clinical trials for NASH, ASH and paediatric NAFLD.
  • IMM-529 – This asset is in the clinical development for the treatment of Clostridium difficile Infections.

The company released a corporate presentation today on ‘Targeting Infectious Diseases With Oral Immunotherapies’. It was presented by the Chief Executive Officer of the company, Dr Gary Jacob.

Some of the segments discussed in the presentation are highlighted below:

US Department of Defense R&D Collaboration Agreements

The company had collaborated with the following Institutes for the development of a Shigella-specific therapeutic:

  • Armed Forces Research Institute of Medical Sciences (AFRIMS) in June 2016
  • Naval Medical Research Center (NMRC) in August 2016
  • Walter Reed Army Institute of Research (WRAIR) in June 2016

Travelan® Commercial Profile

The global market size of Travelan® is US$630 million in 2019, expected to reach US $890M by 2024 at 7% CAGR. If the Travelan® would be approved as a drug to prevent TD, the sale of the drug is expected to reach more than $100 million in the United States.

IMM-124E Drug Development Plan

The company plans to revamp Travelan® for FDA approval to develop it as a drug to prevent Travelers’ Diarrhea in travellers. The process of the drug development plan is represented below:

On 11th April 2019, the company announced its plans to pursue clinical development of IMM-124E as a drug to prevent Travelers’ Diarrhea (TD).

Clostridium difficile Market Opportunity

The therapeutic market is expected to reach over $1.7 billion by 2026 from USD $630 million in 2016 at a CAGR of 15 per cent. Also, the C. difficile infection is a leading cause of gastroenteritis-associated mortality in the U.S. Around 44,500 patients died in 2014 from C. difficile infections in the U.S.

The present therapies to treat C. difficile infection are plagued by significant CDI recurrences underscoring the need for new treatments.

IMM- 529 Drug Development Plan

The company intends to develop IMM-529 as a drug to prevent recurrent Clostridium difficile Infection. The drug development plan would be implemented as per the following steps:

The company released its third quarter FY19 sales results on 15th April 2019. The company witnessed a 66 per cent YoY growth in worldwide sales during the third quarter of FY19. The sales of the Travelan® surged in Australia in Q3, growing 73% YoY. The company also received its first purchase order for Canada during Q3 FY19.

The company’s stock closed the day’s trade at AUD 0.185 (on 17th May 2019). The stock has not performed well during the last few months. It has performed in the negative territory in the previous one month, generating a negative return of 22.92 per cent.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.